| HuMA, Inc.’s R&D program involves recombinant
therapeutic antibodies to molecular targets related to cancer,
transplantation and chronic inflammatory conditions, such as
rheumatoid arthritis, atherosclerosis, and chronic inflammatory
bowel diseases. We focus on molecular targets that were previously
confirmed to be over-expressed in various disease tissues. HuMA’s
core platform, including in-licensed phage display technology,
is designed to elucidate the underlying mechanisms at the target
level. Our original IP claims the recombinant therapeutic antibodies
to these targets and their uses.
HuMA also is conducting preclinical-stage R&D concerning
HGF-neutralizing antibody. The receptor for HGF, cMET, is
a receptor tyrosine kinase that mediates several epithelial
cell functions. Malfunctions in the HGF/cMET pathway have
been linked with various cancers, malaria, Alzheimer’s
disease and rheumatoid arthritis. HGF antibody may offer neutralization
of HGF in vivo and, consequently, prove to be a valid therapeutic
treatment of cancer and a mandatory combined agent for anti-angiogenic
agents. |
Home
